Search clinical trials for: IBI310

Total 367 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Wuhan Union Hospital, China

Recruiting

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Cancer, Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Aarhus University Hospital
Denmark: Danaflex A/S, national distributor of Cochlear Ltd

Completed

Comparative Study of Two Surgical Techniques for Soft Tissue Healing and Implant Stability of Cochlear BI300 Implants.

Hearing Loss, Conductive

Denmark
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Evaluation of IBI302 Injection in nAMD or DME

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers

Advanced Malignant Tumors Lymphomas

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Asthma | Healthy Participants

Australia
Buhai Wang
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Cervical Cancer | Uterine Cervical Neoplasms | Cervix Cancer | Cervical Neoplasms

China
The First Affiliated Hospital of Xiamen University

Recruiting

Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC

Colorectal Neoplasms

China
Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili...

Not yet recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) (HSBRT2402)

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI302 in Patients With nAMD

Neovascular Age-related Macular Degeneration

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients

Neovascular Age-related Macular Degeneration

China
Sichuan University
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients

Stage IV NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients

B-Cell Lymphoma

China
Henan Cancer Hospital

Not yet recruiting

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Gastric Cancer | Gastroesophageal-junction Cancer
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Small Cell Lung Carcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Qian Wenbin

Not yet recruiting

Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

Diffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

Gastric Cancer | Perioperative | Sintilimab

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

AS
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI362 in Participants With Type 2 Diabetes

Type 2 Diabetes

China
Nexus DX

Unknown

Evaluation of the IB10 Sphingotest PCT+ in a Point-of-Care Setting

Sepsis
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Extranodal NK/T Cell Lymphoma, Nasal Type

China
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis

Colorectal Cancer | Liver Metastasis
Henan Cancer Hospital

Recruiting

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

Diffuse, Large B-Cell, Lymphoma

China
Hunan Cancer Hospital
Xiangya Hospital of Central South University; Innovent Biologics (Suzhou) Co...

Unknown

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

China
Guangdong Association of Clinical Trials

Unknown

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Nsclc
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

Type 2 Diabetes

China
Tianjin Medical University Cancer Institute and...
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients (SMART)

Non Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

SCLC

China
Chengappa, K.N. Roy, MD
Stanley Medical Research Institute; Maryland Psychiatric Research Center

Active, not recruiting

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

Schizophrenia

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Myeloid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity

Obesity | Type 2 Diabetes

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Reza Dana, MD
United States Department of Defense; New York Presbyterian Hospital; Bascom Palmer...

Completed

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Corneal Neovascularization | Corneal Graft Failure

United States
Baocai Xing

Recruiting

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
First Affiliated Hospital of Zhejiang University

Unknown

The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Gastric Cancer

China
Aarhus University Hospital

Completed

Stability of the Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery

Hearing Loss - Conductive

Denmark
Sun Yat-sen University

Recruiting

Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

Metastatic | Adenocarcinoma of Small Intestine | Appendix Carcinoma

China

3

Subscribe